The course will provide a comprehensive update on the treatment of thoracic malignancies with special emphasis on the multimodality treatment. To that regard there is a wide participation of thoracic surgeons, chest physicians and oncologists.
At the end of the course participants will be able to:
– have a deeper knowledge of diagnostic modalities for thoracic malignancies
– be familiar with the most up to date form of treatment according to stage
– be able to choose and offer the patient several therapeutic modalities with an explanation of advantages and disadvantages
– be confident in drawing a treatment plan involving several specialists and treatment modalities (surgery, oncology and radiotherapy).
December 2, 2020
14:30
15:0015:00
15:15Start of the connection to the WEBINAR and opening
15:15
15:30Introduction to the course
MODULE I – EARLY DISEASE
I° SESSION
CHAIR:
15:30
15:40Nelson study: what have we learnt and what is left to do?
15:40
15:50Radiologic diagnosis of lung cancer: when is it enough?
15:50
16:00New bronchoscopic techniques: friend or foe?
MODULE I – EARLY DISEASE
II° SESSION
CHAIR:
16:00
16:10Resection vs surveillance for GGOs
16:10
16:20Surgery vs SBRT for operable patients: is there a role?
16:20
16:30Neoadjuvant treatments for early stage lung cancer: is there a role?
MODULE I – EARLY DISEASE
III° SESSION
CHAIR:
16:30
16:40Where do we draw the line for indications for surgery? The truly inoperable patient
16:40
16:50Ecmo for thoracic surgery
16:50
17:00How much can we push minimally invasive surgery?
17:00
17:30Q&A
17:30
Closing the firs webinar module
17:30
18:00Sponsor KOL video
December 3, 2020
14:30
15:00Sponsor KOL video
15:00
15:15Start of the connection to the webinar
15:15
15:30Introduction to the course
MODULE II – ADVANCED DISEASE
I° SESSION
CHAIR:
15:30
15:40Immunotherapy in resectable NSCLC
15:40
15:50News in immunotherapy world in advanced NSCLC: improving the bar
15:50
16:00Neoadjuvant strategies in oncogene addicted tumors: is it now the time?
MODULE II – ADVANCED DISEASE
II° SESSION
CHAIR:
16:00
16:10Oncogene addicted tumors: new OMA’s to know
16:10
16:20SCLC a new dawn or the same old refrain
16:20
16:30Concomitant neoadjuvant chemoRT vs neoadjuvant chemo vs surgery upfront
MODULE II – ADVANCED DISEASE
III° SESSION
CHAIR:
16:30
16:40Treatment of (un)resactable stage III lung cancer
16:40
16:50Oligometastatic disease: when is too much for surgery?
16:50
17:00Multimodality approach for orphan diseases: MPM and SCLC
17:00
17:30Q&A
17:30
Closing of the webinar
17:30
18:00Sponsor KOL video
INFO
International Thoracic Oncology Symposium | Email: info@thoraciconcology.it
ENDORSED BY
DISCLAIMER
The information contained in this website is for general information purposes only. The information is provided by International Thoracic Oncology Symposium and while we endeavour to keep the information up to date and correct, we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability or availability with respect to the website or the information, products, services, or related graphics contained on the website for any purpose. Any reliance you place on such information is therefore strictly at your own risk.
© 2020 International Thoracic Oncology Symposium 2020 – Dev by Dep42